MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments

OBJECTIVE: To evaluate the efficacy of MAP0004, an orally inhaled dihydroergotamine, for acute treatment of migraine when administered at various time points from within 1 hour to more than 8 hours after migraine onset. PATIENTS AND METHODS: This post hoc subanalysis was conducted using data from 90...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tepper, Stewart J., Kori, Shashidhar H., Goadsby, Peter J., Winner, Paul K., Wang, Min H., Silberstein, Stephen D., Cutrer, F. Michael
Natura: Artigo
Lingua:Inglês
Pubblicazione: Mayo Foundation for Medical Education and Research 2011
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3184024/
https://ncbi.nlm.nih.gov/pubmed/21964172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4065/mcp.2011.0093
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi